

Controlled Substance Legislative Update - August 2017 pdmp.alaska.gov

LEGISLATIVE INTENT

It is the intent of the legislature that the seven-day supply limit for an initial opioid prescription under secs. 5, 16, 22, and 33 of [HB 159] and the four-day supply limit for an initial opioid prescription under sec. 28 of [HB 159] may not be considered as a minimum length of time appropriate for an initial prescription.

The United States Centers for Disease Control and Prevention (CDC) guidelines state that a three-day initial prescription of an opioid is sufficient for most cases of acute pain. CDC reported in its March 17, 2017, weekly report that the likelihood of a person's chronic opioid use increases with each additional day of medication supplied after the second day.

Practitioners should use their professional judgment in each case and not interpret the seven-day limit as a direction to prescribe the full seven days or the four-day limit as a direction to prescribe the full four days.

RESPONSIBILITIES WITH THE PDMP DATABASE						
WHAT	WHO	WHEN	WHY			
It is the responsibility of the pharmacist, the individual filling a prescription for federally scheduled controlled substance II, III, or IV, to submit information into the database on a weekly basis. (AS 17.30.200(r))	Pharmacists	July 17, 2017	Nearly half of all U.S. opioid overdose deaths involve a prescription opioid. Nationally, deaths from prescription opioids have more than quadrupled since 1999.			
It is the responsibility of the pharmacist, the individual filling a prescription for federally scheduled controlled substance II, III, or IV, to submit information into the database on a <i>daily</i> basis. <i>AS 17.30.200(r)</i>	Pharmacists	July 1, 2018	Alaska's prescription opioid overdose death rate was more than twice the national rate in 2012.			
It is the responsibility of the practitioner, the individual writing prescriptions or administering federally scheduled II or III controlled substances, or the practitioner's delegate, to review the database prior to writing the prescription or administering the medication. (AS 17.30.200(b))	Practitioners who hold DEA registration numbers	July 17, 2017	 Misuse of prescription opioids is a significant risk factor for starting heroin use. PDMPs have been found to improve patient care and reduce misuse, and diversion of controlled substances 			
A delegate registered with the PDMP may review a patient's prescription history on behalf of the provider. (AS 17.30.200(d))	Delegates must hold a professional license under Title 08 of Alaska Statute	July 17, 2017				
There is no restriction on who may enter data into the PDMP. After registering the office or pharmacy with PMP Clearinghouse, data may be entered into the PDMP through an electronic file transfer or an online universal claim form.	(professionallicense.alaska.gov)					

WHATWHOWHENDispensing less than a 24-hour supply of controlled substances at an inpatient pharmacy for use after discharge (AS 17.30.200(u))All practitioners and pharmacistsJuly 28, 2017Dispensing less than a 24-hour supply of controlled substances in an emergency department (AS 17.30.200(u))July 28, 2017

EXEMPTIONS FROM PDMP USAGE

Administered to an inpatient admitted to a health care facility (AS 17.30.200(k))

Administered at the scene of an emergency, in an ambulance, or in an emergency department (AS 17.30.200(k))

July 17, 2017

Dispensing, prescribing, or administering at a hospice or nursing home that has an inpatient pharmacy (AS 17.30.200(k))

July 17, 2017

nmediately before, during, or within the first 48 hours after surgery or a medical procedure (AS 17.30.200(k))		July 17, 2017
Vriting a nonrefillable prescription for a controlled substance in a quantity intended to last for not more than three ays (AS 17.30.200(k))		July 17, 2017
exempt from the PDMP <u>except</u> when prescribing opioids to an inmate at the time of the inmate's release (AS 7.30.200(u))	Correctional facilities	July 28, 2017
LIMITATIONS ON OPIOID PRESCRIPTIONS		
VHAT	WHO	WHEN
 uration of an initial opioid prescription limited to a seven-day supply for an adult or minor. The prescriber must discuss with the parent or guardian of a minor why the prescription is necessary and the risks associated with the opioid use. A prescriber may issue a prescription for greater than a seven-day supply to an adult or minor patient if, in the professional judgement of the prescriber, more than a seven-day supply is necessary for:	Physicians (AS 08.64.326, AS 08.64.363, AS 08.64.364) Dentists (AS 08.36.315, AS 08.36.355) Advanced Practice Registered Nurses (AS 08.64.270, AS 08.68.705)	July 26, 2017
 of this document, are met. urration of an initial opioid prescription limited to a seven-day supply for an animal patient. A prescriber may issue a prescription for greater than a seven-day supply to an animal patient if, in the professional judgement of the prescriber, more than a seven-day supply is necessary for: management of certain pain, or an owner who is unable to access a practitioner within the time necessary for a refill of the seven-day supply because of a logistical or travel barrier. The prescriber must document in the animal's medical record: the condition requiring the excess of a seven-day supply, and indicate a non-opioid alternative was not appropriate to treat the condition. The board may impose a disciplinary sanction if the board finds that a licensee has prescribed or dispensed an opioid in excess of the maximum dosage. 	Veterinarians (AS 08.98.235, AS 08.98.245)	July 26, 2017
 The prescriber must discuss with the parent or guardian of a minor why the prescription is necessary and the risks associated with the opioid use. A prescriber may issue a prescription for greater than a seven-day supply to an adult or minor patient if, in the professional judgement of the prescriber, more than a four-day supply is necessary for:	Optometrists (AS 08.72.240, AS 08.72.276)	October 24, 2017
OTHER CONTROLLED SUBSTANCE CHANGE	S	
VHAT	WHO	WHEN
oluntary Nonopioid Directive Act n individual or an individual's guardian may execute a voluntary nonopioid directive stating that an opioid may not e administered or prescribed to the individual or the minor. The directive must be in a format prescribed by DHSS nd available in an electronic format.	All Alaskans (AS 13.55.010-110)	July 1, 2019
Insolicited Notifications he board is authorized to provide confidential, unsolicited notification to a pharmacist, practitioner's licensing oard, or practitioner if a patient has received one or more prescriptions for controlled substances in quantities or vith a frequency inconsistent with generally recognized standards of safe practice.	Practitioners and pharmacists (AS 17.30.200(q))	July 26, 2017

Report Cards The Board of Pharmacy may issue to a practitioner periodic un practitioner's opioid prescribing practice with other practitioner report issued under this subsection is confidential and the boards.	Practitioners (AS 17.30.200(t))	July 26, 2017			
REQU	JIREMENTS FOR N	IEW APPLICANTS			
WHAT	WHO	WHEN			
Applicants for licensure must receive education in pain management and opioid use and addiction prior to licensure, unless the applicant has demonstrated to the satisfaction of the board that the applicant does not currently hold a valid federal DEA registration number.			Dentists (AS 08.36.110)	July 1, 2018	
Physicians and optometrists: Applicants for licensure by credentials must demonstrate professional competence in pain management and addiction disorders. The professional competence may include professional experience or professional instruction as proof of professional competence.			Physicians (AS 08.64.200, AS 08.64.205, AS 08.64.209, AS 08.64.225, AS 08.64.250)		
	Optometrists (AS 08.72.120, AS 08.72.170)				
Medical Board will adopt regulations for physician assistants to use and addiction.	Physician Assistants (AS 08.64.107)	July 1, 2018			
CONTIL	NUING EDUCATIO	N REQUIREMENTS			
WHAT			WHO	WHEN	
A licensee must receive no less than two hours of education in the two years preceding application for renewal, unless the lice that the licensee's practice does not include pain management. An applicant for renewal may not be exempted from the requirements of the second of the se	Physicians (AS 08.64.312)	July 1, 2018			
pain management and opioid misuse and addiction, unless the board that the person does not currently hold a valid federal D Medical Board will adopt regulations for physician assistants to	Physician Assistants	July 1, 2018			
use and addiction.	(AS 08.64.107)	·			
A licensee must receive no less than two hours of education in the two years preceding application for renewal, unless the per that the person does not currently hold a valid federal DEA reg	Optometrists (AS 08.72.181) Dentists (AS 08.36.070)	July 1, 2018			
	Advanced Practice Registered Nurses (AS 08.68.276)				
The board is required to identify resources and develop educat animal owner who may be at risk for abusing or misusing an op-	Veterinarians (AS 08.98.050)	July 1, 2018			
	QUESTIO	NS?			
WHAT	WHO	PHONE	EMAIL or WEB ADDRES	S	
PDMP technical questions, including registration and login assistance	Appriss Health	1-855-525-4767			
PDMP program questions	Alaska Department of Commerce,	907-269-8404	akpdmp@alaska.gov		
Note: Questions regarding practice-specific interpretation, enforcement, or discipline should be directed to the appropriate licensing board. Visit the Professional Licensing homepage for program-specific contact information.	Community, and Economic Development (DCCED)		pdmp.alaska.gov professionallicense.alaska.gov		
Patient and provider opioid information & resources	Centers for Disease Control and Prevention (CDC)		www.cdc.gov/drugoverdose	www.cdc.gov/drugoverdose	
	Alaska Department of Health and Social Services (DHSS)		<u>opioids.alaska.gov</u>		